ANI Pharmaceuticals develops, makes, and sells prescription medicines, including rare disease, brand name, and generic drugs. ANIP reports earnings on Thu, Nov 5, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 23 | Oppenheimer | Initiated | Buy | |
| Aug 10 | Guggenheim | Maintained | Buy | |
| Aug 10 | Canaccord Genuity | Target lowered | Hold | |
| Jul 17 | Canaccord Genuity | Initiated | Hold |
Whale Options Flow
90DNo whale options trades in ANIP in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANIP is in one of them and how their past ANIP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ANIP in an article yet. Here's the latest on the wider market.
About Ani Pharmaceuticals
ANI Pharmaceuticals is a biopharmaceutical company based in Princeton, New Jersey. It develops, manufactures, and sells prescription medicines in three areas: rare disease treatments, brand name products, and generic drugs. Its rare disease products include Purified Cortrophin Gel and the ILUVIEN and YUTIQ eye implants, which treat conditions such as diabetic macular edema and uveitis. The company makes its products at its own plants in Minnesota and New Jersey and sells them to patients, physicians, and specialty pharmacies.
- Headquarters
- Princeton, NJ